US Pharma MarketingPfizer looks beyond lung cancer flop as BioNTech, BMS show early activity
Pfizer’s failed Seagen ADC sigvotatug vedotin showed a 2.5-month OS edge in second-line NSCLC in a post-hoc ESMO analysis. Also on Sunday, BioNTech and Bristol Myers Squibb touted early lung cancer data for their PD-L1×VEGF bispecific pumitamig. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next…
MADRID — Pfizer is moving past its late-stage loss in non-small cell lung cancer, pointing to a post-hoc analysis of earlier-line patients who appear to benefit. Also on Sunday, BioNTech and Bristol Myers Squibb touted ...
Source: Endpoints News